Oral squamous cell carcinoma (OSCC) is associated with heavy smoking and drinking, but the molecular pathway of tumorigenesis is not understood. Inactivation of the p53 tumor suppressor gene is likely to play an important role since p53 mutation is frequently found. The p14ARF tumor suppressor gene is functionally linked to p53, because it is activated by oncogenes and causes p53-dependent growth arrest and apoptosis. The relationship between p14ARF and p53 inactivation has not been described for OSCC. We studied 25 cases of OSCC to determine if there is an inverse correlation between p53 mutation and p14ARF inactivation by homozygous deletion or mutation. p53 mutation was found in 16 of 25 cases (64%), including nine missense and seven truncating mutations. While all cases with missense mutations showed abnormal accumulation of p53 protein, there were also ®ve carcinomas which showed increased p53 staining in the absence of mutation. p14ARF deletion or mutation was found in eight cases (32%), six of which also demonstrated p53 mutation. Our ®ndings indicate that OSCC often involves loss of both p14ARF and p53 function and suggest that inactivation of these two tumor suppressor genes are not functionally equivalent during tumorigenesis. Oncogene (2001) 20, 654 ± 658.
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Keywords: p53; mutation; immunohistochemistry; p14ARF; homozygous deletion; oral squamous carcinoma Squamous cell carcinoma of the oral mucosa (OSCC) is associated with heavy smoking and alcohol consumption (Blot et al., 1988; Mashberg et al., 1993) . Multiple genetic changes are thought to contribute to the malignant progression towards OSCC (Califano et al., 1996; Field, 1992) . However, the molecular pathways of oral squamous tumorigenesis are still poorly understood. Mutation of the p53 tumor suppressor gene has been reported to be common among OSCC (Ahomadegbe et al., 1995; Brennan et al., 1995; Erber et al., 1998; Liloglou et al., 1997) . Abnormal staining of the p53 protein is also a frequent ®nding but the relationship between p53 mutation and abnormal staining is generally described as inconsistent (Casey et al., 1996; Hall and Lane, 1994; Xu et al., 1994) .
The p53 protein is activated in response to cellular stress including DNA damage and induces cell cycle arrest or apoptosis. Thus, loss of p53 function in a setting of DNA damage leads to genetic instability, which may be important in the development of malignant disease (Hartwell and Kastan, 1994) . In addition, recent studies in model systems have shown that p53 also induces growth arrest and apoptosis in response to abnormal proliferative signals associated with oncogenes such as myc. This`oncogene checkpoint' function of p53 is mediated through the p14ARF gene, which is encoded by the CDKN2A locus in a unique arrangement of shared exons with the p16 tumor suppressor gene (Chin et al., 1998; Sherr, 1998; Stott et al., 1998) . Oncogenes can upregulate expression of p14ARF, which binds to and inactivates the mdm-2 protein. This releases p53 from the inhibitory eects of mdm-2 and results in p53-mediated growth arrest or apoptosis of the oncogene-expressing cells. Therefore, p14ARF essentially acts as a tumor suppressor gene in a p53 dependent manner.
To understand the role of the p14ARF-p53 tumor suppressor pathway in OSCC, we analysed a set of 25 carcinomas to determine if there was an inverse correlation between p53 mutation and loss of p14ARF function by gene deletion or mutation at the CDKN2A locus. An inverse correlation would support a model of tumorigenesis where p53 and p14ARF lie on a common pathway such that inactivation of either gene is functionally equivalent in abrogating a critical tumor suppressor mechanism (Chin et al., 1998; Sherr, 1998) .
Sixteen of the 25 carcinomas (64%) showed a mutation in the p53 gene (Figure 1 ). In the remaining nine cases, sequencing of the entire coding region of exons 2 ± 11 and all exon-intron junctions showed no mutation of the p53 gene. Among the cases with p53 mutation, there were nine missense mutations (nine of 16, or 56%), all of which resulted in a non-conservative amino acid substitution. Four cases showed nonsense mutations and three cases had a small deletion which resulted in a frameshift and premature stop codon downstream. Thus, a total of seven cases (44%) had a mutation that led to a truncated amino acid sequence.
Immunohistochemical staining was performed to detect abnormal accumulation of p53 protein in the nuclei of carcinoma cells. p53 protein is not detectable, or barely detectable by immunohistochemical staining of frozen sections of normal oral mucosal epithelium. Among the 16 cases with p53 mutation, there was a clear relationship between the type of mutation and the presence of nuclear p53 staining in the carcinoma cells. All nine cases with a missense mutation showed p53 staining, consistent with the presence of an abnormally stabilized, mutant p53 protein. The fraction of carcinoma cells with positive staining varied according to the histologic grade of the carcinoma. In welldierentiated squamous cell carcinomas that showed large tumor islands with a strati®ed architecture and central keratin pearls, staining was observed only in the peripheral cell layers, resulting in a low fraction of labeled nuclei (Figure 2a ). Staining of serial sections with an antibody to the Ki-67 antigen to identify cycling cells suggested that the amount of mutant p53 Figure 1 Two representative electropherograms, each demonstrating a mutation in the p53 gene in oral squamous call carcinoma; (a) sample #28, T to A transition in codon 172; (b) sample #29, one base-pair deletion in codon 161, resulting in a frameshift and downstream premature stop codon. For p53 sequence analysis, DNA was extracted from cryostat sections of OSCC, the p53 gene was ampli®ed by PCR and exons 2 to 11 were sequenced with a combination of automated sequencing (ABI Prism 377 DNA Sequencer, Applied Biosystems) and manual sequencing (Sequenase 2.0 PCR product sequencing kit, USB-Amersham). All mutations were con®rmed by a second PCR and repeat sequencing Figure 2 Immunohistochemical staining for p53 protein, using cryostat sections ®xed with formaldehyde-methanol-acetone and monoclonal antibody DO-7 against p53 protein. Similar staining was obtained with three other monoclonal antibodies that recognize dierent epitopes of the p53 protein. The antigen was visualized with the avidin-biotin horseradish peroxidase complex (Vector Laboratories) using diaminobenzidine as the chromogen and hematoxylin as counterstain; bar represents 100 mm; (a) welldierentiated squamous cell carcinoma with a missense mutation in exon 5 (sample #9), where p53 staining was observed only in the peripheral cell layers of the tumor islands and not in the central, keratinizing cell layers; (b) and (c) moderately dierentiated squamous cell carcinomas with a missense mutation in exon 5 (sample #28) and a missense mutation in exon 8 (sample #49) respectively; compared to the carcinoma in (a), these two carcinomas were less keratinized and showed a greater proportion of p53-positive nuclei; (d) absence of p53 staining in a moderately dierentiated squamous cell carcinoma with a frameshift mutation in exon 5 which results in a premature stop codon (sample #29); (e) p53 staining in dysplastic epithelium that is contiguous with squamous cell carcinoma; staining was seen in the deep half of the dysplastic epithelium but not in the super®cial, keratinizing layers. Both the carcinoma and the dysplastic epithelium showed a missense mutation in exon 4, which was a T to A transition in codon 111 (sample #19); (f) well-dierentiated squamous cell carcinoma (sample #6) with p53 staining of tumor cell nuclei in the peripheral layers of the tumor islands. The pattern was similar to that seen for well-dierentiated carcinomas with a missense mutation (see panel a), but no mutation was found in this sample protein was elevated in cycling cells but not in resting cells or post-mitotic cells. In moderately dierentiated carcinomas, where tumor islands do not show a distinct strati®ed architecture or central keratinization, the fraction of p53-positive nuclei was correspondingly higher (Figure 2b,c) .
In one of the nine carcinomas with a missense p53 mutation, the oral mucosa abutting the invasive lesion showed epithelial dysplasia. The preinvasive, dysplastic epithelium and the carcinoma were both positive for p53 staining (Figure 2e ) and showed the same missense mutation in codon 111 (CTG to CAG). The ®ndings in this case supported the concept that p53 mutation and clonal expansion may precede connective tissue invasion during oral mucosal tumorigenesis (Boyle et al., 1993; Shahnavaz et al., 2000) .
All seven samples with a truncating mutation were negative for p53 staining (Figure 2d) . No staining was observed, regardless of whether an antibody to the Nterminal end of p53, upstream of the truncation site was used or an antibody to the C-terminal end was used. This indicated that truncated p53 proteins were not expressed at detectable levels, in contrast to mutant but full-length p53 proteins.
In ®ve of the nine cases where no p53 mutation was detected after complete sequencing of the coding region, there was unequivocal staining for p53 protein.
The appearance of the p53 staining was indistinguishable from that seen in cases with a missense p53 mutation. Staining of tumor cell nuclei was observed with four antibodies directed against dierent epitopes of the p53 protein. Where the carcinoma formed welldierentiated islands, p53 positive nuclei were characteristically located in the peripheral cell layers (Figure 2f ).
Deletion analysis of the p14ARF exons was carried out on relatively pure preparations of carcinoma cells that were collected from tissue sections by laser capture microdissection (Bonner et al., 1997) . There was less than 5% contamination of carcinoma cells by connective tissue and in¯ammatory cells, as judged by visual inspection of the captured material. Seven of the 25 cases showed deletion of both exon 1b and exon 2 of the p14ARF gene, as shown by marked loss of the ethidium bromide stained band that indicated the ampli®ed exon (Figure 3) . The weak band that was seen in these cases was attributed to PCR ampli®cation of DNA from the small number of contaminating in¯ammatory cells, which often in®ltrated into carcinoma islands. There was complete agreement between deletion of exon1b and that of exon 2, indicating that the region of deletion encompassed most of the CDKN2A locus. As expected, analysis of exon 1a which is part of the p16 gene and lies between exon 1b and exon 2 in this locus, showed deletion of exon 1a in cases with deletion of exon 1b and exon 2.
For the 18 cases that did not show deletion of exon 1b and exon 2, these exons were sequenced to examine for mutations. No mutations were identi®ed in exon 1b. Sequence analysis of exon 2 revealed one case with a four base pair deletion involving codons 81(Arg) and 82(Arg) of p14ARF. This resulted in a change in reading frame from the p14 reading frame to the p16 reading frame, since exon 2 of the CDKN2A locus encodes both p14 and p16, in alternative reading frames (Ruas and Peters, 1998) . The four base pair deletion led to a chimeric protein consisting of the ®rst 80 amino acids of p14ARF fused to the C-terminal 88 amino acids of p16. The wild type sequence was not detected in this case, which agreed with the ®nding of a reduced intensity of the exon 2 fragment in duplex PCR analysis, indicative of a hemizygous deletion (not shown). A recent study demonstrated that the segment of human p14ARF that lies between amino acid residues 83 and 101 is necessary for localizing the p14ARF protein to the nucleolus. The frameshift mutation ARF 1 ± 80 ± p16 69 ± 156 identi®ed here may disrupt the nucleolar localization of ARF and interfere with its ability to stabilize p53 (Sherr and Weber, 2000; Zhang and Xiong, 1999) , although the functional signi®cance of p14ARF exon 2 mutation still remains controversial (Lohrum et al., 2000) .
When the relationship between p53 mutation and p14ARF deletion or mutation was examined, we found that ®ve of the seven cases that showed homozygous deletion of p14ARF exons also had a mutation in p53. Four of these ®ve cases had a missense p53 mutation and one had a frameshift p53 mutation. The one case with a four base pair microdeletion of p14ARF exon 2 also had a nonsense mutation in p53. Two cases with Figure 3 Duplex PCR analysis of exons 1b and 2 of the p14ARF gene, shown in ethidium bromide stained agarose gels. DNA was prepared from carcinoma cells that were isolated from cryostat sections by laser capture microdissection (PixCell II, Arcturus, Mountain View, CA, USA) and used directly for PCR. Upper band: 537 base pair genomic fragment of the GAPDH gene, used as internal PCR control; lower band: 480 base pair genomic fragment of p14ARF exon 1b (a) and 450 base pair genomic fragment of exon 2 (b). Primers used were: exon 1b F-CAGTTAAGGGGGCAGGAGTG, R-AGGGCTGTGTGAA-GGGAGG; exon 2 F-CCCTGGCTCTGACCATTCTG, R-TGAGGCAAGACCGGAGAC; GAPDH F-GAGGTA-GAGGGGTGATGTGG, R-TCTGAGCCAGCCACCAGAG. Lane 1 is the SCC25 oral squamous carcinoma cell line, which has a deletion of exon 2 but retention of exon 1b. Lane 11 is the mock laser microdissection control, where there were no captured cells and no template DNA in the PCR reaction. Lane 12 is the 100 base pair DNA ladder. Lanes 4, 8, 9 and 10 are carcinoma samples (case no. 17, 7, 4, 38 respectively) with homozygous deletion of both exons 1b and 2 of p14ARF. Lane 5 is the nondysplastic epithelium from case #17, showing retention of exons 1b and 2 p53 and p14ARF abnormalities in oral squamous carcinoma G Bradley et al homozygous deletion of p14ARF exons did not have p53 mutation. One of these two cases showed abnormal staining for p53 protein in the absence of p53 mutation, while the second case had negative p53 staining (Table 1a ). In total, 18 patients had p53 mutation or ARF deletion/mutation or both, and they were all smokers or former smokers. Only seven patients had neither p53 mutation nor p14ARF abnormality. Four of these demonstrated p53 immunostaining and three did not, indicating that ARF genotype does not correlate with the amount of p53 expressed in OSCC. Three of these seven patients have never smoked and all three had tumors that demonstrated p53 immunostaining in the absence of p53 mutation. The low frequency of p53 mutation among non-smokers has been reported previously (Koch et al., 1999) , but the abnormal accumulation of p53 protein in the absence of mutation has not been described in these patients. Additional studies are needed to determine if this type of p53 abnormality is characteristic for patients with OSCC who are non-smokers. Our data did not reveal an inverse correlation between p53 mutation and inactivation of p14ARF by deletion or mutation, since six of the eight cases with p14ARF deletion or mutation also had a p53 mutation. Conversely, six of the 16 carcinomas with p53 mutation also had deletion or mutation of p14ARF (Table 1b) .
Lack of an inverse correlation between p14ARF loss and p53 mutation was recently reported for non-small cell lung carcinomas (Sanchez-Cespedes et al., 1999) and astrocytic gliomas (Ichimura et al., 2000) . In contrast, another study of glioblastomas showed that p53 mutation and p14ARF deletion were mutually exclusive (Fulci et al., 2000) . Studies of a variety of tumor cell lines have also demonstrated that genetic alterations of p53 and p14ARF were inversely correlated, suggesting that p53 inactivation and p14 loss were functionally equivalent in critical growth regulatory pathways (Markl and Jones, 1998; Stott et al., 1998) . It was proposed that dierences in the selective pressure to inactivate the p53 pathway might explain the variable relationship between p53 mutation and p14ARF deletion (Fulci et al., 2000) . p53 is activated by a wide range of cellular stresses including DNA damage, hypoxia, metabolic de®ciencies, as well as oncogenic activation. These stimuli appear to signal to p53 through distinct biochemical pathways. In experimental systems, p14ARF was shown to mediate the increase in p53 activity in response to oncogene activation but not the increase in p53 activity after DNA damage (Giaccia and Kastan, 1998; Prives and Hall, 1999) . Further studies are needed to investigate the possibility that distinct patterns of p53 and p14ARF inactivation may be associated with dierent pathways of malignant progression. Another possible explanation of the lack of inverse correlation between p53 and p14 inactivation is that p14 deletion may occur as a result of proximity and overlap of its exons with p16 exons in the CDKN2A locus. The p16 tumor suppressor gene regulates cell cycle progression at the G1/S transition and is commonly inactivated in Head and Neck carcinomas. Thus, the critical event that leads to a growth advantage for malignant cells with deletion or mutation of the CDKN2A exons could be loss of p16 function rather than loss of p14 function.
In conclusion, our analyses of the p53 and p14ARF genes in OSCC indicated that abnormality of these two functionally linked tumor suppressor genes is common in oral carcinomas. Inactivation of p53 and p14ARF do not appear to be functionally equivalent in oral epithelial tumorignesis, which suggests that these genes act in a complex mechanism of multiple biochemical pathways. Further study of both clinical samples with clinicopathologic correlation and tumor cell lines should clarify the mechanism through which p53 and p14ARF inactivation contribute to oral epithelial tumorigenesis.
